Welcome to our dedicated page for Alpha Tau Medical news (Ticker: DRTSW), a resource for investors and traders seeking the latest updates and insights on Alpha Tau Medical stock.
Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) is an Israeli clinical-stage oncology therapeutics company developing Alpha DaRT®, a radium-224–based intratumoral alpha-radiation therapy for solid tumors. The news flow around Alpha Tau centers on clinical trial progress, regulatory interactions, and operational milestones related to this technology.
Company press releases describe ongoing and planned studies of Alpha DaRT in several high-need cancer indications, including recurrent cutaneous squamous cell carcinoma, pancreatic ductal adenocarcinoma, recurrent glioblastoma multiforme, recurrent squamous cell carcinoma of the oral cavity, and locally recurrent prostate cancer. News items highlight first-in-human treatments, such as the first patient treated in a U.S. multi-center pancreatic cancer trial and the first patient treated with Alpha DaRT in the brain for recurrent glioblastoma.
Regulatory and development updates are another recurring theme. Alpha Tau reports Breakthrough Device Designation from the U.S. Food and Drug Administration for multiple indications, participation in the FDA’s Total Product Life Cycle Advisory Program for recurrent GBM, and submission of the first module of a pre-market approval application for Alpha DaRT in recurrent cutaneous squamous cell carcinoma using a modular framework. The company also discloses FDA approval of an Investigational Device Exemption for a pilot study in locally recurrent prostate cancer.
Operational and corporate news includes securing a radioactive material license for a commercial-scale Alpha DaRT manufacturing facility in New Hampshire, interim financial results, and participation in healthcare and investor conferences hosted by organizations such as J.P. Morgan, Piper Sandler, Sidoti, and Jefferies. Investors and observers following DRTS and DRTSW can use this news page to review Alpha Tau’s reported clinical milestones, regulatory steps, manufacturing preparation, and capital markets activities as they relate to the Alpha DaRT platform.
Alpha Tau Medical presented new preclinical data at the 2024 ESTRO Congress, showcasing the abscopal immune effect of Alpha DaRT in pancreatic murine tumor models. The data revealed a significant reduction in distant tumor growth rate, indicating potential benefits for future clinical trials and patient outcomes. CEO Uzi Sofer highlighted the promising results, emphasizing the therapy's potential in combination with immunotherapy.
Alpha Tau Medical announced that CFO Raphi Levy will present at investor conferences in May 2024. The company, known for its alpha-radiation cancer therapy Alpha DaRT™, will participate in events like Guggenheim Securities Radiopharmaceuticals Day and H.C. Wainwright BioConnect Investor Conference.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.